Generic indicators for process quality in oncological care: A compendium
LBI-HTA published the report “Quality of care in oncology and its measurement” in 2011 where international efforts in indicator development are discussed. Therein 17 indicator sets for measuring quality in oncological care were presented as examples. In order to give clinical practice a hands on tool book in the area of cancer care quality indicators, this compendium provides details about generic (i.e. not cancer type specific) process indicators (i.e. not structure or outcome) from this pool of 17 oncological indicator sets.
The focus of this compendium lies on processes after a confirmed diagnosis of cancer. Therefore indicators for preventive care including screening are not covered. Five of the 17 indicator sets did not contain any generic process indicators. All generic process indicators found are listed. 31 generic process indicators that were found in at least two of the 17 indicator sets are described in greater detail in this compendium.
HTA-Project report No. 49b: http://eprints.hta.lbg.ac.at/946
Contact: Nikolaus Patera
Horizon Scanning in Oncology: Decision Support Document No. 21 online
Within the scope of the Horizon Scanning in Oncology project, the LBI-HTA periodically publishes assessments on novel cancer drugs with a likely therapeutical and/or financial outcome. These assessments serve as decision aids for funding agencies and the decision-making network "HTA in hospitals " alike.
February 2012:
Axitinib (AG013736, Inlyta®) for the second-line treatment of metastatic renal cell carcinoma (mRCC) New!
Erlotinib (Tarceva®) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations
Everolimus (Afinitor®) for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin
More